MLYS vs. ZYME, WVE, ORIC, COGT, SIGA, NRIX, DNTH, PHAR, SVRA, and CALT
Should you be buying Mineralys Therapeutics stock or one of its competitors? The main competitors of Mineralys Therapeutics include Zymeworks (ZYME), Wave Life Sciences (WVE), ORIC Pharmaceuticals (ORIC), Cogent Biosciences (COGT), SIGA Technologies (SIGA), Nurix Therapeutics (NRIX), Dianthus Therapeutics (DNTH), Pharming Group (PHAR), Savara (SVRA), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical preparations" industry.
Zymeworks (NYSE:ZYME) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk, media sentiment and community ranking.
Zymeworks currently has a consensus price target of $12.67, indicating a potential upside of 43.78%. Mineralys Therapeutics has a consensus price target of $33.50, indicating a potential upside of 147.78%. Given Zymeworks' stronger consensus rating and higher possible upside, analysts clearly believe Mineralys Therapeutics is more favorable than Zymeworks.
Zymeworks has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500.
Mineralys Therapeutics has lower revenue, but higher earnings than Zymeworks. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.
Zymeworks received 276 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 68.59% of users gave Zymeworks an outperform vote.
Mineralys Therapeutics has a net margin of 0.00% compared to Mineralys Therapeutics' net margin of -249.63%. Mineralys Therapeutics' return on equity of -28.37% beat Zymeworks' return on equity.
92.9% of Zymeworks shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 1.2% of Zymeworks shares are held by insiders. Comparatively, 33.2% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Mineralys Therapeutics had 5 more articles in the media than Zymeworks. MarketBeat recorded 11 mentions for Mineralys Therapeutics and 6 mentions for Zymeworks. Mineralys Therapeutics' average media sentiment score of 0.07 beat Zymeworks' score of 0.04 indicating that Zymeworks is being referred to more favorably in the media.
Summary
Mineralys Therapeutics beats Zymeworks on 9 of the 17 factors compared between the two stocks.
Get Mineralys Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MLYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mineralys Therapeutics Competitors List
Related Companies and Tools
